{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:53:02Z","timestamp":1791478382361,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.htct.2026.106502","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T21:21:15Z","timestamp":1785273675000},"page":"106502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Decoding BCR::ABL1 kinase domain mutations in chronic myeloid leukemia: Implications for tyrosine kinase inhibitor resistance in a South Asian population"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3366-9830","authenticated-orcid":false,"given":"Fatima","family":"Sharif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafia","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maimoona","family":"Roghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikandar Hayat","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.htct.2026.106502_bib0001","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2147\/JBM.S382090","article-title":"Chronic myeloid leukemia, from pathophysiology to treatment-free remission: a narrative literature review","volume":"14","author":"Rinaldi","year":"2023","journal-title":"J Blood Med"},{"key":"10.1016\/j.htct.2026.106502_bib0002","doi-asserted-by":"crossref","first-page":"S376","DOI":"10.3816\/CLM.2009.s.037","article-title":"The chronic myeloid leukemia stem cell","volume":"9","author":"Nicholson","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.htct.2026.106502_bib0003","doi-asserted-by":"crossref","first-page":"7918","DOI":"10.1182\/blood-2024-210443","article-title":"Global trends of burden of chronic myeloid leukemia based on socio-demographic index (SDI): a comparative epidemiological study","volume":"144","author":"Chaulagain","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.htct.2026.106502_bib0004","first-page":"5","article-title":"Cancer statistics, 2015: cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.htct.2026.106502_bib0005","first-page":"935","article-title":"Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia","volume":"8","author":"Cohen","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.htct.2026.106502_bib0006","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","article-title":"2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"39","author":"Apperley","year":"2025","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.htct.2026.106502_bib0007","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11899-016-0306-5","article-title":"Quality of life and long-term therapy in patients with chronic myeloid leukemia","volume":"11","author":"Flynn","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"10.1016\/j.htct.2026.106502_bib0008","doi-asserted-by":"crossref","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","article-title":"Chronic myeloid leukemia, version 2.2024, NCCN clinical practice Guidelines in oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"10.1016\/j.htct.2026.106502_bib0009","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am J Hematol"},{"issue":"19","key":"10.1016\/j.htct.2026.106502_bib0010","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.3390\/cancers13194820","article-title":"Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance","volume":"13","author":"Alves","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.htct.2026.106502_bib0011","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1586\/17474086.2014.900432","article-title":"Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"7","author":"Baccarani","year":"2014","journal-title":"Expert Rev Hematol"},{"issue":"5","key":"10.1016\/j.htct.2026.106502_bib0012","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.htct.2026.106502_bib0013","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/hematology.2023000447","article-title":"Resistance mutations in CML and how we approach them","volume":"2023","author":"Soverini","year":"2023","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"12","key":"10.1016\/j.htct.2026.106502_bib0014","first-page":"13687","article-title":"Detecting T315I BCR-ABL mutants in leukemia between RT-qPCR and conventional Sanger sequencing: a comparative study","volume":"12","author":"Wang","year":"2019","journal-title":"Int J Clin Exp Med"},{"issue":"1","key":"10.1016\/j.htct.2026.106502_bib0015","doi-asserted-by":"crossref","first-page":"175","DOI":"10.7150\/ijbs.86305","article-title":"Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"20","author":"Sun","year":"2024","journal-title":"Int J Biol Sci"},{"issue":"10","key":"10.1016\/j.htct.2026.106502_bib0016","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","article-title":"Chronic myeloid leukemia, version 2.2021, NCCN clinical practice Guidelines in oncology","volume":"18","author":"Deininger","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.htct.2026.106502_bib0017","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/labmed\/lmaa052","article-title":"ABL kinase domain mutations in Iranian chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors","volume":"52","author":"Shojaei","year":"2021","journal-title":"Lab Med"},{"key":"10.1016\/j.htct.2026.106502_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2023.1611518","article-title":"Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia","volume":"29","author":"Hasanova","year":"2023","journal-title":"Pathol Oncol Res"},{"issue":"4","key":"10.1016\/j.htct.2026.106502_bib0019","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.leukres.2013.12.025","article-title":"BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-frequency and clinical outcome","volume":"38","author":"Elias","year":"2014","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.htct.2026.106502_bib0020","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s12288-024-01769-z","article-title":"A retrospective analysis of BCR-ABL-1 kinase domain mutations in frontline TKI resistant chronic myeloid leukemia patients: a single centre experience","volume":"40","author":"Datta","year":"2024","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"5","key":"10.1016\/j.htct.2026.106502_bib0021","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1016\/S2352-3026(19)30027-4","article-title":"Effect of low-level BCR::ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study","volume":"6","author":"Kizilors","year":"2019","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.htct.2026.106502_bib0022","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2009-01-197715","article-title":"Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations","volume":"114","author":"Jabbour","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.htct.2026.106502_bib0023","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.htct.2026.106502_bib0024","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262311285","article-title":"Chronic myeloid leukemia and the T315I BCR::ABL1 mutation","volume":"26","author":"Pierro","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.htct.2026.106502_bib0025","first-page":"469","article-title":"Variables associated with BCR-ABL kinase domain mutation in TKI-resistant patients with chronic myeloid leukemia","volume":"41","author":"Shi","year":"2020","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"8","key":"10.1016\/j.htct.2026.106502_bib0026","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.3390\/ijms26083728","article-title":"Allele-specific PCR for detection of missense mutations in the chimeric BCR:: ABL1 gene causing failure of Tyrosine kinase inhibitor therapy in CML patients","volume":"26","author":"Skripkina","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.htct.2026.106502_bib0027","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.3390\/jcm9123865","article-title":"Molecular testing in CML between old and new methods: are we at a turning point?","volume":"9","author":"Soverini","year":"2020","journal-title":"J Clin Med"}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S253113792600249X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S253113792600249X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:03:26Z","timestamp":1791475406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S253113792600249X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S253113792600249X"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2026.106502","relation":{},"ISSN":["2531-1379"],"issn-type":[{"value":"2531-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decoding BCR::ABL1 kinase domain mutations in chronic myeloid leukemia: Implications for tyrosine kinase inhibitor resistance in a South Asian population","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2026.106502","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"106502"}}